Products
Vilastobart Biosimilar Monoclonal Antibody (CTLA-4) for Research
Cat No.: GMP-Bios-INN-1458
Anti-CTLA4/CD152 therapeutic antibody (Pre-made Vilastobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vilastobart (development code XTX-101) is a humanized monoclonal antibody targeting CTLA-4. It is developed by Xilio Therapeutics for Solid Tumours in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1458-1mg | 1mg | 3090 |
| GMP-Bios-INN-1458-10mg | 10mg | |
| GMP-Bios-INN-1458-100mg | 100mg | |
| GMP-Bios-INN-1458-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vilastobart biosimilar, Whole mAb, Anti-CTLA4/CD152 Antibody: Anti-CTLA-4/CD152/CTLA4/Cytotoxic T-lymphocyte protein 4 therapeutic antibody |
| INN Name | Vilastobart |
| Target | CTLA4/CD152 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | 8g8n:AB:DE:GI:HL:KM |
| 99% SI Structure | None |
| 95-98% SI Structure | 8g2m:HL |
| Year Proposed | 2023 |
| Year Recommended | 2024 |
| Companies | Xilio Therapeutics |
| Conditions Approved | na |
| Conditions Active | Solid Tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
